Company Analysis
Sign in

Replimune Group, Inc. (REPL)

Nasdaq: REPL · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2018
Full chart Alerts Compare
Grade5.0
◀ Past 5.6● Present 4.3▶ Future 5.3
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2026, as filed
Revenuen/a
Net income-$314M-26.9%
Earnings per share$-3.38-10.1%
Operating cash flow-$280M-45.8%
Cash$211M+86.8%
Debt$83.3M+79.6%
Shareholders’ equity$166M-60.0%
Shares, diluted92.8M+15.2%
Return on equity-188.9%
The recordfrom its filings
Filings in 202678
Newest filingNov 10 · 4
Annual reportJun 29, 2026
Quarterly reportOct 28, 2026
Next report due10-Q by Feb 14
Insider sales, 12 monthsn/a
Insider buys, 12 monthsn/a
Patents granted0
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Net income -$271MCash from operations -$246Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
17181920212223242526
As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 10, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Nov 3, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton REPL · research, not advice